



**PB 32 of 2012**

# **National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 3)**

*National Health Act 1953*

---

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the *National Health Act 1953*.

Dated 26 April 2012

**FELICITY McNEILL**  
First Assistant Secretary  
Pharmaceutical Benefits Division  
Department of Health and Ageing

---

## **1 Name of Instrument**

- (1) This Instrument is the *National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 3)*.
- (2) This Instrument may also be cited as PB 32 of 2012.

## **2 Commencement**

This Instrument commences on 1 May 2012.

## **3 Amendments to PB 79 of 2011**

Schedule 1 amends the *National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011)*.

## Schedule 1 Amendments

[1] Schedule 1 Part 1, entry for Carboplatin in the form Solution for I.V. injection 50 mg in 5 mL with manner of administration Injection

*omit:*

			Pfizer Australia Pty Ltd	PF	MP		D
--	--	--	--------------------------	----	----	--	---

[2] Schedule 1 Part 1, entry for Cisplatin

*omit:*

	I.V. injection 10 mg in 10 mL	Injection	Pfizer Australia Pty Ltd	PF	MP		D
--	-------------------------------	-----------	--------------------------	----	----	--	---

[3] Schedule 1 Part 1, entry for Doxorubicin in the form Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial with manner of administration Injection/intravesical

*omit:*

			Adriamycin Solution	PF	MP		D
--	--	--	---------------------	----	----	--	---

[4] Schedule 1 Part 1, entry for Doxorubicin

*omit:*

	Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 20 mg in 10 mL single dose vial	Injection/ intravesical	Adriamycin Solution	PF	MP		D
--	---	----------------------------	---------------------	----	----	--	---

[5] Schedule 1 Part 1, after entry for Doxorubicin - Pegylated Liposomal in the form Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL with manner of administration Injection and brand Caelyx

*insert in the columns in the order indicated:*

			Lipodox	ZF	MP	C1568 C1795 C1796 C3905 C3910 C3911	D
--	--	--	---------	----	----	--	---

- [6] Schedule 1 Part 1, after entry for Doxorubicin - Pegylated Liposomal in the form Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL with manner of administration Injection and brand Caelyx

*insert in the columns in the order indicated:*

			Lipodox 50	ZF	MP	C1568 C1795 C1796 C3905 C3910 C3911	D
--	--	--	------------	----	----	--	---

- [7] Schedule 1 Part 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL with manner of administration Injection/intravesical

*omit:*

			Pharmorubicin Solution	PF	MP		D
--	--	--	------------------------	----	----	--	---

- [8] Schedule 1 Part 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL with manner of administration Injection/intravesical

*omit:*

			Pharmorubicin Solution	PF	MP		D
--	--	--	------------------------	----	----	--	---

- [9] Schedule 1 Part 1, entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL with manner of administration Injection

*omit:*

	I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL	Injection	Camptosar	PF	MP	C3184	D
			Hospira Pty Limited	HH	MP	C3184	D

*substitute:*

	I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL	Injection	Hospira Pty Limited	HH	MP	C3184	D
--	---	-----------	---------------------	----	----	-------	---

- [10] Schedule 1 Part 1, entry for Mitozantrone

*omit:*

	Injection 10 mg (as hydrochloride) in 5 mL	Injection	Pfizer Australia Pty Ltd	PF	MP		D
--	--	-----------	--------------------------	----	----	--	---

**[11] Schedule 1 Part 1, entry for Mitozantrone in the form Injection 25 mg (as hydrochloride) in 12.5 mL with manner of administration Injection**

*omit:*

			Pfizer Australia Pty Ltd	PF	MP		D
--	--	--	--------------------------	----	----	--	---

**[12] Schedule 1 Part 1, entry for Oxaliplatin in the form Powder for I.V. infusion 100 mg with manner of administration Injection**

*omit:*

			Winthrop Oxaliplatin	WA	MP	C3900 C3901 C3930 C3939	D
--	--	--	----------------------	----	----	----------------------------------	---

**[13] Schedule 1 Part 1, entry for Vincristine in the form I.V. injection containing vincristine sulfate 1 mg in 1 mL with manner of administration Injection**

*omit:*

			Pfizer Australia Pty Ltd	PF	MP		D
--	--	--	--------------------------	----	----	--	---

**[14] Schedule 2, entry for Ondansetron in the form I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL with manner of administration Injection**

*omit:*

			Pfizer Australia Pty Ltd	PF	EMP	C3050		1	0	
--	--	--	--------------------------	----	-----	-------	--	---	---	--

**[15] Schedule 2, entry for Ondansetron in the form I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL with manner of administration Injection**

*omit:*

			Pfizer Australia Pty Ltd	PF	EMP	C3050		1	0	
--	--	--	--------------------------	----	-----	-------	--	---	---	--

**[16] Schedule 3, omit entry for WA**

**[17] Schedule 5, before entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd**

*insert:*

Bleomycin	Powder for injection containing bleomycin sulfate 15,000 I.U.	Injection	Bleo 15K	1	\$34.35	\$65.24
-----------	---	-----------	----------	---	---------	---------

**[18] Schedule 5, entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd**

*omit from the column headed 'Listed Drug':*

**Bleomycin**

**[19] Schedule 5, entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd**

*omit from the column headed 'Form':*

**Powder for injection containing bleomycin sulfate 15,000 I.U.**

**[20] Schedule 5, entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd**

*omit from the column headed 'Manner of Administration':*

**Injection**

#### **Note**

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the *Legislative Instruments Act 2003*. See <http://www.frli.gov.au>.